Pharmacological comparison of the potential antidepressant UP 614-04 with viloxazine and imipramine; behavioral studies

General Pharmacology
J MeignenF V DeFeudis

Abstract

1. Several behavioral tests were used to compare the pharmacological activity of the potential antidepressant UP 614-04 with those of viloxazine and imipramine. 2. Orally-administered UP 614-04, like viloxazine, reduced locomotor activity in mice, and, like viloxazine and imipramine, it antagonized the hypothermia or ptosis induced by reserpine or tetrabenazine and the hypothermia induced by a high dose of apomorphine. 3. UP 614-04 antagonized oxotremorine-induced hypothermia, and to a lesser extent, oxotremorine-induced tremors, indicating that it possesses some CNS anticholinergic activity. 4. Both imipramine and viloxazine were more potent than UP 614-04 in potentiating yohimbine toxicity in mice. 5. Orally-administered UP 614-04 potentiated d-amphetamine-induced stereotypy to a greater extent than viloxazine, but to a lesser extent than imipramine. 6. Intraperitoneally-injected UP 614-04 was much more potent than viloxazine in increasing tryptamine convulsive potential in rats, indicating that it might exert an inhibitory action on monoamine oxidase. 7. These results indicate that UP 614-04 has a behavioral profile that is consistent with an antidepressant action, but that it differs from imipramine and viloxazine.

References

Jan 1, 1978·European Journal of Pharmacology·A J PuechP Simon
Aug 1, 1976·Canadian Journal of Physiology and Pharmacology·W Lippman, T A Pugsley
Feb 17, 1973·Lancet·F J Bereen
Nov 1, 1967·The British Journal of Psychiatry : the Journal of Mental Science·A Coppen
Nov 1, 1972·Journal of the Neurological Sciences·H L KlawansW J Weiner
Dec 1, 1965·Archives of General Psychiatry·W E Bunney, J M Davis
Jan 1, 1981·Pharmacology & Therapeutics·M F Sugrue
Apr 1, 1960·Proceedings of the Society for Experimental Biology and Medicine·D H TEDESCHIE J FELLOWS
Jan 1, 1961·Psychopharmacologia·P L CARLTON
Dec 1, 1961·Archives Internationales De Pharmacodynamie Et De Thérapie·F HERRM P CHAREST
Apr 1, 1963·Biochemical Pharmacology·R KATOP VASSANELLI
Aug 1, 1963·British Journal of Pharmacology and Chemotherapy·R M QUINTON
Oct 1, 1974·British Journal of Clinical Pharmacology·P F Bayliss, S M Duncan

Related Concepts

1-methyl-3-(2'-methyl-morpholino)-2H-benzimidazol-2-one
Metazoa
Anticonvulsants
Thymoleptics
Apokinon
Behavior, Animal
Drug Interactions
Tofranil
Levopa
Morpholines

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.

Chromatin Regulation and Circadian Clocks

The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.